New Phase IIa data for RESP-X revealed at ERS Congress 2026
Infex Therapeutics has presented new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa (Pa).
The results were presented at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain.
Pa is a critical factor in up to 30% of NCFB cases, leading to recurring episodes of life-threatening infection – there are currently no approved preventative treatments.
Pa-positive NCFB patients treated with a single dose of RESP-X experienced a reduction in reported annualised exacerbation rate, from 3.4 in the 12 months prior to dosing to 1.2 during the six-month study period. Across all patients dosed with RESP-X, only one exacerbation meeting Hill/EMBARC criteria was observed.
Microbiology data showed that all Pa isolates collected during the study continued to encode the RESP-X target (PcrV), consistent with the complete target coverage reported in May, and additionally showed reductions in sputum Pa burden following treatment.
The analysis also showed reductions in inflammatory biomarkers following treatment, alongside an improvement in patient-reported quality of life scores. The data also confirmed strong lung exposure in the 10mg/kg cohort, with RESP-X detected in the epithelial lining fluid at a level equivalent to 1.9% of serum concentration, supporting the drug’s ability to reach the site of infection.
Together with date reported in May 2026, the study concluded that dosing at three-month intervals could offer a viable approach to reducing exacerbation rates in these patients.
“These new analyses reinforce our confidence in RESP-X as a potential first anti-virulence therapy for Pseudomonas-colonised NCFB patients,” said Dr Peter Jackson, CEO of Infex Therapeutics. “For a population with no approved preventative treatment, the data showing a meaningful reduction in annualised exacerbations is an encouraging result, supporting onward clinical development and commercialisation.”
